Drug Profile
Sodium phosphate - Zeria
Alternative Names: Monobasic sodium phosphate monohydrate/dibasic sodium phosphate anhydrous; Phosribbon Combination Granules; Z-521Latest Information Update: 10 Dec 2021
Price :
$50
*
At a glance
- Originator Zeria
- Class Laxatives; Phosphates
- Mechanism of Action Phosphate replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypophosphataemia
- No development reported Osteomalacia; X-linked dominant hypophosphataemic rickets
Most Recent Events
- 16 Apr 2015 No recent reports on development identified - Preregistration for Osteomalacia (In children) and X-linked dominant hypophosphataemic rickets (In children) in Japan (PO)
- 25 Dec 2012 Registered for Hypophosphataemia in Japan (PO)
- 15 May 2012 Preregistration for Osteomalacia (in children) in Japan (PO)